Have a feature idea you'd love to see implemented?
Let us know!
AMLX Amylyx Pharmaceuticals Inc
Price (delayed)
$4.99
Market cap
$339.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.44
Enterprise value
$267.15M
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company's product candidature includes AMX0035, a
Highlights
Amylyx Pharmaceuticals's debt has decreased by 41% YoY and by 15% from the previous quarter
Amylyx Pharmaceuticals's revenue has soared by 56% YoY but it has decreased by 25% from the previous quarter
The quick ratio has decreased by 27% YoY but it has increased by 4.4% from the previous quarter
AMLX's EPS has dropped by 135% since the previous quarter and by 105% year-on-year
Amylyx Pharmaceuticals's net income has shrunk by 133% QoQ and by 128% YoY
Key stats
What are the main financial stats of AMLX
Market
Valuations
Earnings
Shares outstanding
68.08M
Market cap
$339.73M
Enterprise value
$267.15M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.3
Price to sales (P/S)
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.89
Revenue
$298.76M
EBIT
-$162.36M
EBITDA
-$161.24M
Free cash flow
-$59.56M
Per share
Balance sheet
Liquidity
EPS
-$2.44
Free cash flow per share
-$0.88
Book value per share
$3.84
Revenue per share
$4.39
TBVPS
$4.88
Total assets
$332.16M
Total liabilities
$70.85M
Debt
$3.14M
Equity
$261.31M
Working capital
$256.64M
Debt to equity
0.01
Current ratio
4.66
Quick ratio
4.49
Net debt/EBITDA
0.45
Margins
Efficiency
Dividend
EBITDA margin
-54%
Gross margin
53.7%
Net margin
-55.5%
Operating margin
-59.5%
Return on assets
-38.3%
Return on equity
-46.2%
Return on invested capital
-71.7%
Return on capital employed
-62%
Return on sales
-54.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMLX stock price
How has the Amylyx Pharmaceuticals stock price performed over time
Intraday
1.84%
1 week
4.39%
1 month
59.94%
1 year
-69.03%
YTD
-66.1%
QTD
54.01%
Financial performance
How have Amylyx Pharmaceuticals's revenue and profit performed over time
Revenue
$298.76M
Gross profit
$160.36M
Operating income
-$177.76M
Net income
-$165.87M
Gross margin
53.7%
Net margin
-55.5%
The company's operating margin has shrunk by 192% QoQ and by 41% YoY
Amylyx Pharmaceuticals's net income has shrunk by 133% QoQ and by 128% YoY
The company's operating income has shrunk by 119% YoY and by 119% QoQ
Amylyx Pharmaceuticals's revenue has soared by 56% YoY but it has decreased by 25% from the previous quarter
Growth
What is Amylyx Pharmaceuticals's growth rate over time
Valuation
What is Amylyx Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.3
P/S
1.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.89
AMLX's EPS has dropped by 135% since the previous quarter and by 105% year-on-year
The equity has declined by 32% year-on-year and by 19% since the previous quarter
AMLX's P/B is 20% below its last 4 quarters average of 1.6
Amylyx Pharmaceuticals's revenue has soared by 56% YoY but it has decreased by 25% from the previous quarter
The price to sales (P/S) is 41% lower than the last 4 quarters average of 1.9
Efficiency
How efficient is Amylyx Pharmaceuticals business performance
Amylyx Pharmaceuticals's ROE has plunged by 154% from the previous quarter and by 94% YoY
Amylyx Pharmaceuticals's ROA has plunged by 150% from the previous quarter and by 89% YoY
The company's return on invested capital has shrunk by 136% QoQ and by 85% YoY
AMLX's return on sales is down by 48% year-on-year
Dividends
What is AMLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMLX.
Financial health
How did Amylyx Pharmaceuticals financials performed over time
The current ratio has declined by 30% year-on-year but it is up by 4% since the previous quarter
The quick ratio has decreased by 27% YoY but it has increased by 4.4% from the previous quarter
Amylyx Pharmaceuticals's debt is 99% less than its equity
Amylyx Pharmaceuticals's debt has decreased by 41% YoY and by 15% from the previous quarter
The equity has declined by 32% year-on-year and by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.